Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan as an immunomodulatory agent in acute heart failure
2007-007953-30Phase 3Active
- Sponsor
- Fundación Investigación y Desarrollo en el Área Cardiovascular
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of levosimendan in Acute Heart Failure (AHF) and chronic heart failure (CHF) (2 arms), sponsored by Fundación Investigación y Desarrollo en el Área Cardiovascular. Primary endpoints: Primary endpoint: anti-inflammatory and oxidative stress effect of levosimendan, Change in proinflammatory mediators and 2 more. Started Feb 2008; status: active.
02
Drugs
levosimendan
03
Conditions
Acute Heart Failure (AHF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2007-007953-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007953-30.